Loading evidence section…
Loading evidence section…
Supporting records preserved for this report
35 locally preserved candidate records. Metadata adds research context; it is not a medical claim.
PROJECT NARRATIVE Understanding the complex, bidirectional interrelationship mechanisms between sleep and substance use disorders is a foundational step in the pursuit of prevention and novel therapeutics. This project contributes in an innovative way to the understanding of how sleep disturbance is associated with neurocircuit dysfunction and may exacerbate withdrawal symptoms in those with co-occurring cannabis and alcohol use disorder. In addition, this project aims to examine if objective sleep disturbance can be modified using a behavioral intervention and subsequently improve neurocircuit dysfunction and withdrawal severity.
Research Narrative As access to cannabis has increased dramatically, it is imperative to understand how to approach cannabis use among individuals with alcohol use disorder (AUD) who also use cannabis. The proposed research will compare the effects of a harm reduction intervention (instruction to switch from a high THC product to a low THC/high CBD) product versus a no intervention control condition (continue to use THC like you normally do) in a sample of cannabis users who wish to reduce or quit drinking. If the hypotheses of the proposed research are supported, the dissemination of the research would have an immediate public health impact by educating individuals and health care providers about the relative benefits of switching from high potency THC products to a product with lower THC and higher CBD.
PROJECT NARRATIVE This project aims to determine whether cannabidiol (CBD) is effective in treating alcohol use disorder (AUD) comorbid posttraumatic stress disorder (PTSD). To address this aim, we will conduct a clinical trial in which we administer CBD to fifty individuals with AUD comorbid with PTSD, and assess alcohol intake and PTSD symptoms.
PROJECT NARRATIVE This project is a critical step in assessing the effects of cannabidiol as a candidate medication treatment for youth alcohol use disorder. Medications could help bolster psychosocial interventions for youth struggling with alcohol use problems and reduce the likelihood of transitioning into severe, persisting alcohol use disorder in adulthood, thereby significantly reducing costs to the healthcare system and society.
Combat-exposed Veterans and military personnel have a higher risk of developing posttraumatic stress disorder (PTSD) than civilians and often use alcohol to alleviate their PTSD symptoms, which can render them more susceptible to alcohol use disorders (AUDs). It is well documented that individuals with PTSD comorbid with AUD have more intense alcohol cravings and faster relapse during withdrawal than those with AUD only, making Veterans uniquely suspectible. Recently, the cannabinoid system has emerged as a signaling pathway common to stress and alcohol dependence and withdrawal. Therefore, it is important to examine this pathway in the PTSD and alcohol dependence and withdrawal comorbidity condition and to evaluate innovative therapeutic strategies that target the cannabinoid system. These therapeutic strategies may help to reduce anxiety behavior and alcohol craving during rehabilitation of affected Veterans. Therefore, this project is highly relevant to the VA mission for patient care and rehabilitation.
In alcohol dependent individuals, abstinence from drinking is accompanied by negative emotional symptoms such as anxiety that can be relieved by renewed drinking. This form of "self-medication" is believed to be a driving force for continued excessive alcohol consumption. Preliminary evidence indicates that dysfunctional endocannabinoid signaling contributes to withdrawal-related anxiety and excessive alcohol consumption, and the overall goal of this project is to investigate the therapeutic benefit provided by selective endocannabinoid clearance inhibitors for the treatment of alcohol dependence.
Combat-exposed Veterans and military personnel have a higher risk of developing posttraumatic stress disorder (PTSD) than civilians and often use alcohol to alleviate their PTSD symptoms, which can render them more susceptible to alcohol use disorders (AUDs). It is well documented that individuals with PTSD comorbid with AUD have more intense alcohol cravings and faster relapse during withdrawal than those with AUD only, making Veterans uniquely suspectible. Recently, the cannabinoid system has emerged as a signaling pathway common to stress and alcohol dependence and withdrawal. Therefore, it is important to examine this pathway in the PTSD and alcohol dependence and withdrawal comorbidity condition and to evaluate innovative therapeutic strategies that target the cannabinoid system. These therapeutic strategies may help to reduce anxiety behavior and alcohol craving during rehabilitation of affected Veterans. Therefore, this project is highly relevant to the VA mission for patient care and rehabilitation.
In alcohol dependent individuals, abstinence from drinking is accompanied by negative emotional symptoms such as anxiety that can be relieved by renewed drinking. This form of "self-medication" is believed to be a driving force for continued excessive alcohol consumption. Preliminary evidence indicates that dysfunctional endocannabinoid signaling contributes to withdrawal-related anxiety and excessive alcohol consumption, and the overall goal of this project is to investigate the therapeutic benefit provided by selective endocannabinoid clearance inhibitors for the treatment of alcohol dependence.
In alcohol dependent individuals, abstinence from drinking is accompanied by negative emotional symptoms such as anxiety that can be relieved by renewed drinking. This form of "self-medication" is believed to be a driving force for continued excessive alcohol consumption. Preliminary evidence indicates that dysfunctional endocannabinoid signaling contributes to withdrawal-related anxiety and excessive alcohol consumption, and the overall goal of this project is to investigate the therapeutic benefit provided by selective endocannabinoid clearance inhibitors for the treatment of alcohol dependence.
In alcohol dependent individuals, abstinence from drinking is accompanied by negative emotional symptoms such as anxiety that can be relieved by renewed drinking. This form of "self-medication" is believed to be a driving force for continued excessive alcohol consumption. Preliminary evidence indicates that dysfunctional endocannabinoid signaling contributes to withdrawal-related anxiety and excessive alcohol consumption, and the overall goal of this project is to investigate the therapeutic benefit provided by selective endocannabinoid clearance inhibitors for the treatment of alcohol dependence.
PROJECT NARRATIVE This project aims to determine whether cannabidiol (CBD) is effective in treating alcohol use disorder (AUD) comorbid posttraumatic stress disorder (PTSD). To address this aim, we will conduct a clinical trial in which we administer CBD to fifty individuals with AUD comorbid with PTSD, and assess alcohol intake and PTSD symptoms.
Project Narrative Alcohol addiction poses a significant threat to the global population where even individuals who complete treatment for this disorder have a propensity towards alcohol relapse, especially during times of stress. It is well established that during alcohol abstinence, the hypothalamic-pituitary-adrenal (HPA) axis, which is mediated by endocannabinoid (eCB) activity, is dysregulated; as such, the current proposal aims to investigate the effects of protracted alcohol withdrawal and stress on HPA axis activity and voluntary alcohol consumption. The proposed studies will focus on the prelimbic cortex as a region mediating top-down control over HPA function and cognitive behaviors associated with relapse, and will investigate activity of the eCB system and GABA release in this region as targets for therapeutic action in alcohol addiction.
PROJECT NARRATIVE The goal of this proposal is to conduct a randomized, placebo-controlled trial comparing the effects of hemp- derived, full-spectrum cannabidiol (fs-CBD, which contains a small amount of THC and other cannabis plant components), relative to hemp-derived, broad-spectrum CBD (bs-CBD, which is the same as fs-CBD except that it does not contain THC) and placebo, on alcohol consumption, behavioral AUD phenotypes and the gut microbiome, among adults with alcohol use disorder (AUD). Understanding whether hemp-derived fs-CBD offers benefits for AUD has tremendous public health relevance because existing AUD medications show only modest efficacy, and while pure CBD has recently garnered interest as a potential AUD treatment option, emerging data suggest that it may be more effective when combined with other cannabinoids, as in the proposed trial. Further, given that fs-CBD is the most commonly used commercial CBD product in the US (and limited research has been done testing its effects), results could have immediate public health impact and be rapidly integrated into clinical care.
Research Narrative As access to cannabis has increased dramatically, it is imperative to understand how to approach cannabis use among individuals with alcohol use disorder (AUD) who also use cannabis. The proposed research will compare the effects of a harm reduction intervention (instruction to switch from a high THC product to a low THC/high CBD) product versus a no intervention control condition (continue to use THC like you normally do) in a sample of cannabis users who wish to reduce or quit drinking. If the hypotheses of the proposed research are supported, the dissemination of the research would have an immediate public health impact by educating individuals and health care providers about the relative benefits of switching from high potency THC products to a product with lower THC and higher CBD.
Research Narrative As access to cannabis has increased dramatically, it is imperative to understand how to approach cannabis use among individuals with alcohol use disorder (AUD) who also use cannabis. The proposed research will compare the effects of a harm reduction intervention (instruction to switch from a high THC product to a low THC/high CBD) product versus a no intervention control condition (continue to use THC like you normally do) in a sample of cannabis users who wish to reduce or quit drinking. If the hypotheses of the proposed research are supported, the dissemination of the research would have an immediate public health impact by educating individuals and health care providers about the relative benefits of switching from high potency THC products to a product with lower THC and higher CBD.
Project Narrative (Relevance) The naturally-occurring, non-psychoactive phytocannabinoid cannabidiol (CBD) has been shown to benefit several aspects of behavior and cognition relevant to addiction without producing any of the intoxicating or psychotomimetic effects typically associated with tetrahydrocannabinol (THC). However, CBD has not been extensively examined in humans with addictive disorders, and limited data exists on CBD's safety in human alcohol use disorder (AUD) populations. This study investigates the safety and impact of CBD on AUD-related domains in AUD patients to provide information about the therapeutic potential and mechanism of CBD's effects in the treatment of alcoholism.
In alcohol dependent individuals, abstinence from drinking is accompanied by negative emotional symptoms such as anxiety that can be relieved by renewed drinking. This form of "self-medication" is believed to be a driving force for continued excessive alcohol consumption. Preliminary evidence indicates that dysfunctional endocannabinoid signaling contributes to withdrawal-related anxiety and excessive alcohol consumption, and the overall goal of this project is to investigate the therapeutic benefit provided by selective endocannabinoid clearance inhibitors for the treatment of alcohol dependence.